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ABSTRACT 
 
Site Directed Mutagenesis of Severe Acute Respiratory Syndrome (SARS) Cornavirus 
Nsp 15 Endoribonuclease (April 2006) 
 
 
K. Maravet Baig 
Department of Biology  
Texas A&M University 
Fellows Advisor:  Dr. Linda A Guarino 
                                 Department of Biology, Biochemistry, and Entomology 
 
In 2002-2003 SARS Coronavirus (SARS- CoV) spread throughout the world 
resulting in a 10% death rate. With little known about SARS-CoV, research must be done 
in order to understand the viral mechanism for structure based drug design in the future. 
The purpose of this research is addition to the current body of knowledge concerning 
SARS-CoV proteins, especially that of the Nsp15 endoribonuclease and its activity. 
 Nsp15 is a non-structural protein of SARS-CoV with endoribonuclease activity. 
Nsp15 recognizes and cleaves at uracil with a Mn2+ cofactor; (Endoribonucleases cut in 
the interior of RNA strands). It was hypothesized that the uracil recognition may be 
indicated by four conserved asparagine residues. To test this, one of the conserved 
asparagine residues was mutated for analysis. 
Site directed mutagenesis of Nsp15 with a QuickChange kit was performed. The 
4th asparagine, N, was mutated to alanine in one sample and to serine in another sample, 
making N4A and N4S mutants respectively. The 4th amino acid was chosen due to the 
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flanking amino acid’s known ability to affect activity. Nsp15 forms a hexamer, if the 
mutation caused the hexamer conformation to be disrupted, activity would be affected. 
 N4A and N4S mutant proteins were created, and their catalytic activities were 
tested. N4F, another mutant protein was tested, where phenylalanine replaced asparagine 
in the 4th amino acid position.  Dilutions of the three mutants were tested in order to 
compare the mutant activity with the wild type Nsp15 activity. N4S and N4A showed 
activity, but the N4F mutant did not.  
Since N4F had no activity, it was inferred that the mutation caused a 
conformational change in the protein thereby affecting activity. Since hexamerization is 
protein concentration dependent, different concentrations should be tested in order to find 
out if the protein is active at higher concentration, or if it forms hexamers. A 
determination of the binding affinity of the mutant Nsp 15 for the known co-factor Mn2+ 
should also be conducted as well as the examination of conformational changes brought 
about by addition of Mn2+. Lastly, failure to bind the RNA substrate may cause inactivity; 
this possibility should also be tested. 
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INTRODUCTION 
 
 
SARS-CoV the Causative Agent of SARS 
Coronaviruses are pathogens known to cause respiratory disease in humans (15).  
The Severe Acute Respiratory Syndrome (SARS) Coronavirus spread throughout China, 
Canada, and 30 other countries in the winter of 2002-2003.  A death rate of 10% was 
estimated from the 8,000 known cases (28, 31); this mortality rate was staggering to the 
scientific community.  Until the SARS outbreak, the known human coronaviruses caused 
“cold-like” symptoms, and were not usually life threatening.   Within animal populations, 
especially that of avians and felines, coronavirus infection is much more severe; in 
retrospect, the human mortality rate probably should not have been unanticipated.  SARS 
was first hypothesized to be a mutant strain of a pre-existing coronavirus, however, DNA 
sequence analysis proved this theory wrong showing that SARS was, in fact, a novel 
coronavirus.  In April of 2003, the CDC (Centers for Disease Control and Prevention) 
announced that the full-length genetic sequencing of the genome of the SARS-associated 
coronavirus (SARS Co-V) had been completed (20).  
 
______________ 
This thesis follows the format of the Journal of Virology. 
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A coronavirus isolate similar to the SARS-CoV genome was found in civet cats of the 
exotic meat markets in China.  This information suggested that SARS had “jumped 
species” (Zoonotic transfer) from animals to humans, as was the case for HIV, West Nile, 
and other recently emerged viruses (22). 
SARS-CoV as Compared with Other Coronaviruses 
SARS coronavirus shares many characteristics with other members of the 
coronavirus family.  SARS-CoV particles are irregularly-shaped, with club-shaped 
peplomers extending from the outer envelope.  The peplomers give the virus a crown-like 
appearance, thus the Latin word corona, meaning crown.  The SARS-CoV genome also 
has similarities and differences with other coronaviruses.  Many positive-stranded RNA 
viruses, such as SARS-CoV, produce a single polyprotein or either separate non-
structural and structural precursor polypeptides that are cleaved by virus-encoded or host-
encoded proteinases to render functional subunits (6). 
The SARS RNA genome (32 kb) has a 5’ cap, and a 3’ poly (A) tail.  Proteins for 
viral RNA synthesis are encoded at the 5’ end of the SARS-CoV genome; four viral 
structural protein genes, S, M, E, and N; and several (around eight) presumed accessory 
genes.  This characteristic is retained throughout coronaviruses (14, 26, 29). Although 
eukaryotic RNAs are usually monocistronic, it was discovered that 27 different genes 
were coded for in a single RNA.  This was explained by the synthesis of several 
subgenomic RNAs and by proteolytic cleavage of two large polyproteins encoded by the 
virus.  Both of these processes are unique to the virus and, therefore, represent potential 
targets for antiviral activity. (26, 29, 3, 14)  
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  One potential target for research is non-structural protein 15 (Nsp 15), which has 
been shown to be an endoribonuclease that uses Mn2+ as a cofactor (3). To better 
understand the mechanism of Nsp15 function and its role in viral replication, a set of site-
directed mutant versions of Nsp15 will be constructed.  These mutant proteins will be 
purified and tested for biological activity.  The information gained from this study will be 
useful in future attempts to identify enzyme inhibitors that could potentially control virus 
replication.  
Objective of this Research Endeavor 
Drug treatment of SARS during the epidemic was largely ineffective.  Previous 
efforts to develop vaccines for avian and feline coronaviruses have also proven 
unsuccessful, probably due to the presence of many different strains of coronaviruses 
coupled with their high rate of mutation.  For this reason, research in the area of 
structure-based drug design offers the most promising hope in controlling future 
outbreaks. 
Anti-viral medication for the treatment of SARS-CoV must be highly specific in 
order to inhibit the enzymatic activity of the viral Nsp 15 endoribonuclease, but not 
inhibit similar host cells proteins.  With the high level of specificity required, inquiries 
must be made concerning the processes that are unique to the virus, and not commonly 
shared by the host cell.  Research concerning Nsp 15 endoribonuclease has lead to better 
understanding of the viral machinery, and more specifically the structure and activity of 
Nsp 15, which is the primary target for manipulation. 
The goal of this research concerned Nsp15 and its potential role in synthesis of 
subgenomic RNAs.  Nsp 15, an endoribonuclease that cleaves on the 5’ end of uridylates 
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could potentially be involved in this process.  The goal was to conduct a 
structure/function analysis of Nsp 15 endoribonuclease in order to define residues that are 
essential for activity.  Site directed mutagenesis was conducted in order to make mutant 
versions of Nsp 15 endoribonuclease.  The mutant proteins were analyzed to determine 
the effect of the amino acid substitutions on the catalytic activity.  One mutant was found 
to have no activity.  With this result, future research should include Nsp 15 inquires 
regarding Mn2+ binding, RNA binding, and conformational effects on Nsp15 brought 
about by the mutation. 
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CHAPTER I  
LITERATURE REVIEW  
 
 
A Brief History of SARS Coronavirus 
Severe acute respiratory syndrome coronavirus (SARS-CoV) was first discovered 
in Guangdong Province, China in the fall of 2002.  In February 2003, after failed attempts 
to control the virus, the World Health Organization (WHO) was alerted of the crises.  In 
this same month, the general public became aware of the virus after a woman from Hong 
Kong died while visiting her family in Toronto, thereby spreading the virus to North 
America.  The eventual spread of the virus to 30 countries catalyzed a worldwide effort to 
discover the cause of SARS, and how it could be controlled.  It was discovered that 
SARS-CoV was not simply a mutant of a pre-existing coronavirus, but was a novel 
coronavirus with a possible Zoonotic origin (2).  
Although most evidence for species jump has labeled the civet cat as the Zoonotic 
agent, recent research suggests that the civet may have merely served as a source of viral 
magnification.  Sequence analysis of SARS-CoV obtained from Chinese Horseshoe bats 
showed that the Chinese Horseshoe bats may have been the origin of the novel 
coronaviral strain (16). The fairly recent Zoonotic jump may be a result of the instability 
of the SARS -CoV genome.  Evidence suggests that the mutation rate of the SARS-CoV 
genome, along with several open reading frames (ORFs) may play a role in the virulence 
of SARS-CoV as well as contribute to the possibility of a SARS epidemic anywhere in 
the world (10, 13). 
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Research continues on SARS in order to better understand the viral mechanism 
and structure so that anti-viral treatments, as well as better ways of containment may be 
designed.  The following provides a brief review of recent SARS-CoV publications as 
pertinent to Nsp 15 endoribonuclease research.  
Newly Discovered Way of SARS-CoV Transmission 
In 2005, Wang et al. (30) conducted research on the detection of SARS 
coronavirus in human excrement from Xiao Tang Shan Hospital and the 309th Hospital 
of the Chinese People's Liberation Army.  Through Wang’s research, it was revealed that 
SARS-CoV could be spread through the feces of those infected with the virus. 
Electropositive filter media particle was used in order to concentrate the SARS-CoV 
taken from the sewage of two hospitals in Beijing with SARS patients.  Cell culture along 
with semi-nested RT-PCR, and gene sequencing was used to verify the SARS-CoV RNA 
in the sewage.  No live SARS-CoV was detected in the previously mentioned assays, but 
it was found that the coronavirus has the ability to survive at 4 ºC for 14 days and at 2 º C 
for 2 days.  With these findings, it is now know that the excrement of SARS-CoV 
patients must be handled and disposed of with great care (30). With the possibility that 
SARS-CoV could still be spread today even in human excrement, more insight to the 
proteins coded for by the virus is necessary. 
The Immunology of Infection with SARS-CoV 
Zhang et al (33) proposed that patients with SARS-CoV who recovered from or 
died as a result of the virus were thought to have different neutralizing antibody (Nab) 
responses.  Temporal changes in S glycoprotein-specific neutralizing antibody (Nab) and 
N protein-specific antibodies were analyzed.  The patients that survived SARS-CoV 
infection had higher and prolonged levels of N protein-specific and S glycoprotein-
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specific Nab responses (33).  This suggested the probability of antibody responses in 
determining the definitive disease outcome of SARS-CoV patients (33).  
SARS-CoV Proteins and Their Role in Immunity 
SARS-CoV codes for both structural and non-structural proteins.  Buchholz et al 
(4) explored the importance of the structural proteins by expressing them in parainfluenza 
virus (PIV) type 3 vector BHPIV3.  Since SARS-CoV is a respiratory virus, this 
influenza vector provided immunization of the major sites of SARS-CoV transmission, 
also common in influenza.  One of the structural proteins investigated was S (spike) 
glycoprotein.  It was found that vaccination with BHPIV3 expressing S offered total 
protection against SARS-CoV in the lower respiratory tract, and partial protection in the 
upper respiratory tract.  These results imply that S glycoprotein may act as the best 
neutralizing antigen of SARS-CoV (4). 
Structural Proteins and Structural Analysis of SARS-CoV  
Structural proteins have also been investigated for a better understanding of 
SARS-CoV and possible drug design.  In December 2005, Bartlam et al. researched the 
configuration of SARS-CoV structural proteins (1).  As mentioned earlier, the RNA 
genome of SARS-CoV encodes eight accessory proteins, four structural proteins, and 
sixteen non-structural proteins.  As the structure of SARS-CoV macromolecules are 
elucidated, functions of the virus such as replication, transcription, and the fusion of viral 
and host membranes can be better comprehended.  The main protease and spike protein 
(structural) fusion core have been studied at length with the endeavor of creating 
therapeutics against SARS-CoV (1, 12, 8).  The structures and functions of most SARS 
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proteins remain unknown necessitating further study on their structure, as well as the 
ultrastructure of SARS-CoV (1).  
The surface ultrastructure of SARS-CoV was explored with atomic force 
microscopy. (18) This research was the first direct scale nanometer characterization of 
the surface ultrastructures of SARS-CoV particles.  The virion was directly visualized; 
dimensions for the structural proteins were provided with quantitative measurements. 
After treatment with hydroxyoctanoic acid, the corona, or crown like, appearance of large 
protrusions in the envelope were measured (18).  The surface of each single SARS-CoV 
was surrounded with at least 15 spherical spikes having a diameter of 7.29 +/- 0.73 nm as 
seen with high-resolution images.  This is in agreement with that of S glycoprotein which 
was predicted earlier using the genomes of SARS-CoV (18).  Using the S glycoprotein 
prediction, Zhang et al. hypothesized that the disease outcome of individuals infected 
with SARS-CoV was correlated with the antibody response against SARS-CoV. 
Site Directed Mutagenesis and Structural Protein Function  
Spike (S) glycoprotein, a SARS viral envelope component, has the ability to 
induce an immune response. Research on the importance of S glycoprotein and the 
receptor, angiotensin converting enzyme II (ACE II) has been conducted, and has proven 
promising in the area of drug design. (32) Neutralizing antibodies, (NAbs) against SARS-
CoV S glycoprotein has experimentally been shown to be protective in animals infected 
with the pseudo-viral pathogen.  Empirical research suggests a possible way to stop the 
viral mechanism by interfering with the ligand (S glycoprotein) binding to the receptor 
(ACE II) (32).   
Pseudovirus-based assays were used to evaluate the impact of viral entry and 
immunogenicity; the binding cleft in the S glycoprotein was evaluated, and 8 basic amino 
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acids were removed by site directed mutagenesis, and replaced with alanine.  With this 
removal, it was found that mice vaccinated via DNA failed to produce NAbs.  Point 
mutations were made in the amino acid sequence with varying results.  R441A stopped 
viral entry as well as immune response; however, R453A only prevented viral entry (32). 
The site directed mutagenesis assay can be used with other nonstructural proteins of 
SARS-CoV in order to bring about changes in the activity of the protein via structural 
changes.  
Catalytic Site of a SARS-CoV Structural Protein  
Cinanserin, serotonin antagonist, has been found to inhibit the SARS-CoV 3C-
like proteinase (3CLpro).  Because 3CLpro is fundamental to the viral life cycle, it may be 
one of the best known targets for structure based drug design.  Chen et al. studied a large 
data base of drugs in order to compare structural information of the existing drugs with 
that of crystallographic structure of the binding region of 3CLpro.  After treatment with 
Cinaserin, it was found that the activity was decreased, and in tissue samples inhibition 
was seen.  Though this drug may inhibit 3CLpro, better proteins for inhibition may be 
found (5).  Because of the high mutation rate of the SARS-CoV proteins, more 
information needs to be obtained on all SARS-CoV proteins, such as the nonstructural 
proteins, for structure based drug design to be an effective treatment.  
 SARS-CoV Nonstructural Proteins 
The SARS-CoV RNA genome encodes proteins essential for genome replication 
and RNA transcription.  These proteins are encoded as large polyproteins which are 
eventually proteolytically processed by virus-encoded proteinases producing mature 
replicases.  Antibodies against SARS-CoV proteins were generated against predicted 
20 
replicase proteins.  Antibodies were used to identify and characterize Nsp1, Nsp2, Nsp3, 
Nsp4, Nsp5, Nsp8, Nsp9, Nsp12, Nsp13, Nsp14, Nsp15, and Nsp16.  These 12 proteins 
were predicted to be mature replicase proteins in SARS-CoV-infected Vero cells. 
Immunoblot analysis was used to predict protein sizes.  6 hours post-infection similar 
patterns of “punctate perinuclear” and distributed “cytoplasmic foci” with all replicase 
antibodies were detected using immunofluorescence microscopy. Co-localizations of 
replicase protein Nsp8 with Nsp3 and Nsp2 in cytoplasmic complexes were determined 
with “dual-labeling” studies (23). 
Assay of SARS-CoV Nonstructural Proteins  
Similarities between Murine Hepatitis Virus (MHV) and SARS have given 
researchers a venue to obtain more information on SARS-CoV and its associated 
proteins.  In this study, SARS-CoV nucleocapsid and Nsp 12 were detected through anti-
MHV virions and RNA-dependent RNA polymerase.  The results from this study 
confirmed the hypothesized processing pattern for mature SARS-CoV replicase proteins. 
The findings suggested conservation of protein epitopes in the replicase and nucleocapsid 
of SARS-CoV as well as group II coronavirus, MHV (23, 27).  Research results also 
indicate ability of replicase antibodies to detect SARS-CoV-infected cells as early as 6 
hours post infection; this information adds to the body of literature used for studies of 
SARS-CoV inhibition, replication, and diagnosis.  Independent labs continue to research 
the individual proteins of SARS-CoV, such as Nsp 12. (23) 
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ORFs Yield More Information on SARS-CoV Nonstructural Proteins 
RNA codes for various open reading frames (ORFs) that may ultimately be 
transcribed into protein (24, 34). SARS- CoV has several open reading frames; the 
positive stranded RNA genome of SARS–CoV encodes ORF1 (9, 7).  Of the 
nonstructural proteins, Nsp 1 and Nsp2 have been found to contain the most variable 
sequences, while the other 14 nonstructural proteins seem to be more conserved.  
Deletions in the coding sequence of Nsp 2 were performed in order to determine the 
importance of Nsp 2 in viral replication.  As result of the deletion, the viral growth and 
RNA synthesis were slowed.  Resulting from this research by Graham et al, a better 
method for the determination of other nonstructural proteins, such as Nsp 9 or Nsp 15, 
was established by using reverse genetic systems (9, 7).  
Functions of Nonstructural Proteins in Greater Detail 
It was hypothesized by Li et al. that the interaction of Nsp 10 with the cellular 
oxido-reductase system would cause extensive cytopathic effect (17).  To test this idea, 
yeast two hybrid assay was used to screen for proteins that interacted with Nsp 10 in the 
cDNA library of a human embryo lung (17).  As indicated by the results, apart from 
BTF3 and ATF5, two subunits of cellular RNA polymerase, Nsp10 also interacted 
specifically with the NADH 4L subunit and cytochrome oxidase II (17).  A change in the 
activity of the NADH-cytochrome as well as depolarization of the inner mitochondrial 
matrix was found as a result of the Nsp10 protein gene in the transfected lung fibroblast. 
This result indicates one possible viral mechanism used by SARS-CoV in infection (17).  
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Previous SARS-CoV Nsp 15 Studies 
Bhardwaj et al. (3) showed that SARS-CoV Nsp15 protein was a ribonuclease 
that cleaved 5’ uridylates in RNA substrates.  Through experimental results, manganese 
was found to be the preferred cofactor (3).  Moreover, if the 5’ or 3’ terminus was 
blocked, the cleavage pattern remained unchanged indicating that it was an 
endoribonuclease.  Both Double- and single-stranded RNAs acted as substrates for the 
endoribonuclease, although kinetics were faster for single-stranded RNA indicating that it 
was the preferred substrate.  Mn2+ was found to act as a co-factor, and was necessary for 
the best enzyme activity.  Other divalent metals, such as Mg2+, were tested, but produced 
less endoribonuclease activity.  Contingent to the level of endoribonuclease activity of 
Nsp 15 was the concentration of Mn2+.  Using Tryptophan fluorescence, Mn2+ was shown 
to induce conformational changes in the protein in a concentration-dependent manner.  
An orthologous protein of another coronavirus was tested, and found to display 
endoribonuclease activity.  It was hypothesized that Nsp 15 endoribonuclease is common 
to the coronavirus family (3). 
Nsp 15 Research Influence by another RNase 
 Numata et al (21) showed that substrate specificity of a different uridine-specific 
RNase in the RNase T2 family could be changed from uridine to guanine by mutation of 
asparagine 71 to serine or threonine.  With this change in specificity, more information 
was obtained about the active site, and substrate binding. (21) Given the similarity of the 
RNA substrates and uridylate specificity of T2 RNase, to Nsp 15 endoribonuclease, it 
was hypothesized that similar mutations in Nsp 15 may render information about the 
catalytic sites of Nsp 15, as well as its activity.  In Nsp 15, the fourth amino acid, 
23 
asparagine, was mutated to serine (N4S) and alanine (N4A) and the activity of the 
mutants were tested.  
Why SARS-CoV Research is Important 
Recurrence of SARS-CoV still poses a threat because the causative agent 
lingering in animal reservoirs is not wholly understood.  Sporadic cases continue to be 
reported, and serve as a reminder that research on SARS-CoV must continue (19).  With 
increasing knowledge of SARS-CoV and its proteins, better ways of treating the virus, 
and containing the virus should future outbreaks occur, will be possible.  
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CHAPTER II 
 MATERIALS AND METHODS 
 
 
Site Directed Mutagenesis 
Oligonucleotides for N4A and N4S were ordered from Invitrogen™ with the 
desired mutations; the 4th amino acid, asparagine, N, was mutated to alanine, A, in one 
oligonucleotide and to serine, S in the other.  In order to construct the N4A and N4S 
mutants, a QuikChange™ kit purchased from Stratagene© was employed; before usage, 
the kit was stored at -20°C as suggested by the manufacturer.  The QuikChange™ kit 
provided Quik Solution™ used in the procedure (it was suggested to leave the Quick™ 
Solution off ice while preparing the samples due to its ability to quickly freeze).  The kit 
also included 10X reaction buffer, a dNTP (deoxy-nucleotide triphosphate) mix, and a 
Pfu mix. 
Quick Solution, 10X reaction buffer, dNTP mix, Pfu mix, along with mutagenic 
primers, template DNA, and H2O were added together making the mutagenesis reaction 
with a final volume of 50µL; the final volume of 50 µL was chosen arbitrarily.  The 
solution per volume added can be seen in Table 2.1. 
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 10X Reaction 
Buffer 
 
 
 
 
 
5 µL 
 
 
 
 
 
 
 
 
 dNTP mix 
 
 
 
 
 
 
 
 
1 µL 
 
 
 
 10 ng/µL 
Template 
DNA (Nsp 15 
WT) 
 
 
1 µL 
 
 
 
 Quick Solution© 
 
 
 
3 µL 
 
 
 
100ng/µL N4A 
(or N4S) 
primer 1 
 
 
1.25 µL 
 
 
 
 Pfu mix (DNA 
polymerase) 
 
 
 
1 µL 
 
 
 
100ng/µL N4A 
(or N4S) 
primer 2 
 
 
1.25 µL 
 
 
 
H2O 
 
 
 
 
36.5 µL 
 
 
 
 
                    Table 2.1: Solution per volume added for mutagenesis protocol 
 
 
The primers were obtained in a 1 µg/µL solution.  Further dilutions had to be 
made in order to aliquot 100ng/µL primer solutions.  Since 1µg/µL is equivalent to 1000 
ng/µL a 1:10 dilution was performed; 1 µL of primer + 9 µL of H2O for 10 µL, or, 2 µL 
of primer + 18 µL of H2O for 20 µL.  The larger volume was used.  The template DNA 
(Nsp 15 WT) was available in a 3.05 ng/µL solution. (It should be noted that the 
procedures as described were performed for both N4A and N4S.) 
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 In order to obtain the desired 10 ng/µL, it was observed that 3.05 ng/µL was the 
same as 3050 µg/µL.  A total volume of 500 µL was arbitrarily chosen due to 
convenience; 1.6 µL of DNA was calculated and added to 498.8 µL of H2O which 
yielded the desired concentration of 10 ng/µL of template DNA.  Once the entire 
mutagenesis solution was prepared, as seen in Table 2.1, the sample was transported on 
ice to the Eppendorf Mastercycler PCR for Polymerase Chain Reaction, which amplified 
the plasmid containing Nsp 15 and incorporated the desired mutations.  
The mutagenesis PCR consisted of 20 cycles which served to melt the DNA, 
anneal the primers, and finally elongate the DNA with the desired mutations.  First, the 
mutagenesis sample was held at 95°C for 1 min, followed by 18 cycles of 95°C for 50 
sec, 55°C for 50 sec, and 68°C for 6 min.  The final cycle was 68°C for 6 min.  After 
PCR, the mutagenesis sample was removed from the Eppendorf Mastercycler PCR and 
placed on ice for a few seconds (see Figure 2.1 for thermocycler machine). 
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Figure 2.1: Picture of thermocycler machine 
 
 
Transformation into XL-10 Gold Competent Cells  
One µL of the restriction enzyme Dpn I was added to the sample in order to digest 
the parental DNA strand, leaving only the newly replicated DNA.  (Dpn I was used as a 
consequence of the methylated guanine; cleavage using DpnI is between A and T.)  The 
treated sample was put in a 37 °C water bath for 1 hour.  The XL-10 Gold Cells 
(competent cells) for transformation were removed from the -80°C freezer and were 
allowed to melt while on wet ice.  After the competent cells had liquefied, 2µL of β-
Mercaptoethanol was added to the cells.  
28 
The mixture was left on ice for 10 minutes.  3 µL of each mutagenesis reaction 
was pipetted into the competent cells.  The cells were not mixed by pipetting up and 
down; the tube was flicked in order to carefully mix without damaging the cells.  The 
sample was then incubated on ice for 30 minutes.  After this, the sample was heat-
shocked for precisely 30 seconds by placing the mixture in a 42ºC water bath.  The 
sample was not shaken.  Upon removal from the water bath, the sample was placed on ice 
for 2 minutes. 900 µL of pre-warmed SOB media was added.  Following this addition, 
the sample was taped on its side in a shaking incubator and allowed to shake at 225 rpm 
for 1 hour at 37ºC.  After shaking, 100 µL, 150 µL, and 250 µL of the transformation 
were spread, while near an open flame, on to 2 separate LB agar plates with ampicillin. 
The residual transformation reaction mixture was stored at 4 ºC overnight.  The spread 
LB-Amp+ plates were placed upside down and incubated overnight at 37ºC to allow 
colonies to grow. 
Purification of Mutant DNA 
A well isolated colony (see Figure 2.2) was picked from the LB-Amp+ plate with 
the end of a sterile wooden pick; this was also performed near an open flame.  The colony 
was then placed into 5 mL of LB medium with ampicillin.  The culture was then allowed 
to shake at 300 rpm overnight at 37 ºC.   After the required time had elapsed, the bacterial 
cells were harvested at 6000 rpm for 15 minutes at 4 ºC in a Beckman Model J2-21 
centrifuge using a JA-14 rotor.  The bacterial pellet formed during centrifugation was 
resuspended in 4 mL of Buffer P1 (provided in the Qiagen© plasmid kit).  The P1 buffer 
contained RNase A, and to ensure the bacteria were completely resuspended, the sample 
was pipetted up and down.  After complete resuspension, 4 mL of Buffer P2 was added to 
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the sample.  The sample tube was inverted 5 times to mix, and was incubated at room 
temperature for 5 minutes.  4 mL of chilled Buffer P3 was added to the sample, and 
immediately inverted 5 times.  The sample was then incubated on ice for 20 minutes. 
 
 
 
 
Figure 2.2:  Example of colonies in LB-ampicillin plate 
 
 
After incubation, the sample was centrifuged at 20,000 rpm at 4 ºC for 30 
minutes.  The supernatant contained the desired plasmid DNA, and was removed.  The 
supernatant was centrifuged again at 20,000 rpm at 4 ºC for 15 minutes.  The supernatant 
was removed promptly.  240 µL (collection 1) of the now cleared supernatant was 
removed for later use on an analytical gel.  The QIAGEN-tip 100 was equilibrated by 
applying 4 mL Buffer QBT.  The column was allowed to empty by gravity filtration.  The 
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tip was completely drained before the successive step was performed.  The supernatant 
was then loaded onto the QIAGEN-tip 100 and entered the resin by the force of gravity. 
240 µL (collection 2) of the flow through was saved for analytical purposes.  The 
QIAGEN-tip 100 was washed with 2 x 10 mL Buffer QC. 240 µL (collection 3) of the 
wash fractions were removed for analytical purposes.  After this, the DNA was eluted 
with 5 mL of Buffer QF.  100 µL (collection 4) of the elution was saved for analytical 
purposes.  3.5 mL of room-temperature isopropanol was added to the elution to 
precipitate out the DNA.  After this addition, the sample was immediately mixed, 
followed by centrifugation at 3750 rpm at 4 ºC for 60 minutes.  Henceforward, the 
supernatant was poured off.  
The DNA pellet form from the centrifugation was washed with 2 mL of room-
temperature 70% ethanol.  The supernatant was carefully poured off; the DNA pellet 
remained stuck to the side of the tube.  The pellet was then air dried for 10 minutes.  The 
DNA pellet was then re-dissolved in adequate volume of pH 8.0 TE buffer.  Collections 
1-4 were saved overnight at -20 ºC as well as the final purified DNA  
Throughout the course of the max prep assay, care was taken not to shear the 
genomic DNA; because of this, the buffers were not mixed by vortex.  To minimize salt 
precipitation with the purified DNA, the buffers were kept at room temperature.  The 
purified DNA pellet produced by the max prep was around 500 µg as suggested by the 
Qiagen™ protocol.  Care was taken not to throw out the isopropanol pellet due to its 
loose attachment to the side of the tube, and clear appearance.   
For the DNA agarose gel analysis, collections 1-4, purified DNA, and standard 
molecular weight marker were run; since N4A and N4S were both purified, there were 8 
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total collections.  The DNA gel was run at 110 volts.  Table 2.2 expresses the volumes 
used to run on the gel of the collections, loading dye, and H2O. 
 
 
 Sample Dye H2O 
Collections 1-
4 
18 µL 2 µL - 
Purified DNA 
(N4A & N4S) 
10 µL 2 µL 8 µL 
 
Table 2.2: Loading volumes for analytical agarose gel 
 
 
Optimum density readings of the DNA were taken.  OD readings should be 
between 0.8-1. 1 mL of H2O was placed into a UV spectrophotometer cuvette to calibrate 
the spectrophotometer in the UV region.  5 µL was then added to the H2O.  The readings 
for both N4A and N4S were obtained, and were used in determining the amount of DNA 
to add for each PCR mixture.  
Sequencing of Purified DNA  
To confirm the correct DNA mutation had taken place, sequencing PCR was run. 
The promoter and terminator were diluted 4:36 respectively and were pipetted into 
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separate PCR tubes.  The mutant DNA was added to the PCR tubes containing promoter 
and terminator along with Big Dye.  All volumes added can be found in Table 2.3. 
 
 
DNA (N4A) 
6 µL 
(N4A) 
6 µL 
(N4S) 
4 µL 
(N4S) 
4 µL 
T7 
promoter/terminator 
(promoter) 
2 µL 
(terminator) 
2 µL 
(promoter) 
2 µL 
(terminator) 
2 µL 
Big Dye 2 µL 2 µL 2 µL 2 µL 
 
Table 2.3: Volumes added to PCR tubes for sequencing 
 
 
H2O was added to each of the above mixtures to make a total volume of 20 µL for 
each tube.  For N4A, 10 µL of H2O was added; for N4S, 12 µL of H2O.  The sequencing 
PCR cycle was run on the samples: 2 minutes at 94°C (1X) 94°C for 15 seconds, 55°C 
for15 seconds, 72°C for 1 minute, and 72°C for 2 minutes (30X).  After this, all contents 
were transferred into 1.5 mL tubes, and 5 µL of EDTA (250 mM) was added.  To this 
mixture, 60 µL of room temperature 100% ETOH was added.  After this addition, the 
mixture was spun at full speed at 4 °C for 15 minutes on a centrifuge.  The supernatant 
was discarded, and the pellet was washed with 100 µL of 70% ETOH.  The pellet was 
allowed to dry and was sent for sequencing  
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Protein Expression Assay for N4A and N4S 
One µL of the mutant DNA was pipetted into 1 mL of thawed Star (S) competent 
cells.  The cells were then incubated on ice for 30 minutes.  Following this, the cells were 
heat shocked in a 42°C water bath for 45 seconds.  0.5 mL of SOB media was added to 
the cells, and the cells were shook for 37°C for 1 hour.  100 µL of the cells were spread 
onto an LB agar plate with ampicillin.  The plate was incubated at 37 °C overnight.  
After overnight incubation, 5 mL LB media was pipetted into a 50 mL tube.  5 µL 
of ampicillin was added to the 50 mL tube.  After this, 5 well isolated colonies were 
chosen from the plate and placed into the tube.  This procedure was carried out beside an 
open flame.  The culture was then placed in a shaker for 4 hours at 37 °C. The bacterial 
culture became cloudy.  While the culture was shaking, 1 L of LB media was prepared. 
25 g of LB was added to 1L MiliQ purified water in a 4 L flask.  The LB was then 
autoclaved for 20 minutes on the liquid cycle, with no dry time.  The entire 5 mL culture 
was transferred into 1 L of warmed media; 1 mL of 50 mg/mL Ampicillin was added. 
The 1 L culture was then placed in a 37 °C shaker for 4 hours.  The OD (optimum 
density) of the DNA was tested after 4hours; the OD was done in the visible light region 
at 600 nm.  The readings for both N4A and N4S were obtained.  After OD had been 
reached, the culture was cooled at 4°C; 0.5 mL of IPTG was added after adequate 
cooling.  The cooled culture was placed at 16°C in a shaker for 36 hours.   
The culture was centrifuged at 5,000 rpm for 10 minutes using the JA-14 rotor; 
the supernatant was discarded.  The pellet was resuspended in 20 mL Nsp Buffer (see 
Table 2.4). 
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Desired Concentrations Volumes used to attain 
desired amounts 
300 mM NaCl 30 mL of 5 M NaCl 
50 mM Tris ( pH 7.9) 25 ml 1 M Tris 
10 % Glycerol 50 mL 
2 mM β- Mercaptoethanol* 28 µL  
 
Table 2.4: Volumes for Nsp Buffer 
*add fresh to 200 mL of NaCl, Tris, and Glycerol 
 
 
H2O was added to make the final volume 500 mL for the entire Nsp Buffer.  Only 
200 mL of this volume was used; β-Mercaptoethanol was added to the 200 mL 
solution. 30 mg of Lysozyme was added to the resuspended sample; it was 
incubated on ice for 10 minutes.  Following this, the sample was sonicated for 2 
minutes at 4°C.  The duty cycle was set to 50%, and the output control set to 4.5. 
20 µL of the sonicated sample was saved for 10% PAGE gel analysis.  The 
sample was then centrifuged at 16,000 rpm for 30 minutes, with a JA-20 rotor.  20 
µL of the supernatant was saved for gel analysis. All remaining supernatant was 
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mixed onto a Talon nickel affinity column (after the column had been prepared; 
see Figure 2.3). 
 
 
 
 
    Figure 2.3: Talon Nickel affinity column 
 
 
The Talon column was prepared by adding 2 mL Talon resin to the plastic 
column.  This was followed by a 5 mL H2O wash, 2 mL MES wash, and finally a 
3 mL Nsp Buffer wash.  The resin was resuspended into 5 mL Nsp Buffer, and 
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transferred into 50 mL tube.  The resin was centrifuged on a medium speed for 10 
minutes.  The supernatant was poured off but the pellet of resin was saved.  The 
Talon resin + supernatant from the sample shook on ice for 20 minutes.  This was 
poured on to the column and allowed to empty by gravity flow.  20 µL of the flow 
through was saved for gel analysis.  The column was then washed with 20 mL of 
Nsp Buffer.  175 µL of 10 mM Imidazole was added to 15 mL of the Nsp Buffer; 
this mixture was used to wash the column. 20 µL of wash flow through was saved 
for gel analysis.  3 x 1 mL of Nsp Buffer + 625 µL 250 mM Imidazole was used 
as a second wash; 20 µL of each 1 mL elution was saved for gel analysis.  
Loading dye was added to the samples.  The samples were placed on a hot plate 
for 3 minutes before loading into the 10% PAGE gel.  The amount of protein 
sample and loading dye used can be found in Table 2.5.  
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Extraction phase DNA Loading Dye (1X or 2X) 
Total 4 µL 20 µL 1X 
Load 4 µL 20 µL 1X 
Flow Through 4 µL 20 µL 1X 
Elute 1 10 µL 10 µL 2X 
Elute 2 10 µL 10 µL 2X 
 
     TABLE 2.5: Volumes loaded into 10% SDS PAGE gel 
 
 
The volumes used for the 10% SDS PAGE gel can be found in Table 2.6. 
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Protein Gel (10% SDS gel) 
30% Acrylamide 12 mL 
H2O 14.5 mL 
1.5M Tris (pH 8.8) 8.96 mL 
10% SDS 360 µL 
10% APS 240 µL 
TEMED 24 µL 
 
Stacking Gel 
30% Acrylamide 1.28 mL 
0.5M Tris (pH 6.8) 2 mL 
H2O 4.56 mL 
10% SDS 80 µL 
10% APS 80 µL 
TEMED 8 µL 
 
Table 2.6: Volumes used for preparing the 10% SDS PAGE gel 
 
 
Fast Protein Liquid Chromatography (FPLC) purification 
Low salt and high salt wash buffers were made for calibration of the FPLC.  Tris, 
NaCl, Glycerol, and β-Mercaptoethanol were added in quantities as described in Table 
2.7.  Water was also added to the buffers in order to make a total buffer stock of 500 mL 
for each. Β-Mercaptoethanol was added fresh to aliquot of the stock buffer. 
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Low Salt Buffer 
50 mM Tris ( pH 7.9) 25 mL 
100 mM NaCl 10 mL 
5% Glycerol 25 mL 
H2O 440 mL 
2 mM β-Mercaptoethanol* 21 µL 
 
High Salt Buffer 
50 mM Tris 25 mL 
1 M NaCl 100mL 
5% Glycerol 25 mL 
H2O 350 mL 
Β-Mercaptoethanol* 14 µL 
 
Table 2.7: Low salt and high salt FPLC column buffers  
*must add fresh 
 
 
The FPLC was allowed to calibrate with the high and low salt buffers before the 
sample was prepared.  After the calibration, the protein sample was diluted to a lower salt 
concentration, from 300mM to 100 mM.  The remaining volume of elute 1 and elute 2 (1 
mL each) that were not used in the 10% SDS PAGE gel were added together (2 mL).  4 
mL of no NaCl buffer, containing .1 mM EDTA and 50 mM Tris was added to the 
elutions; 4 mL of 100 mM NaCl buffer (low salt buffer) was added to make the total 
volume 10 mL.  The 10 mL sample was transferred into 2 mL tubes and micro-
centrifuged at full speed for 10 minutes at 4°C.  The samples from the tubes were 
recombined and injected into the port hole of the FPLC intake column.  The FPLC 
collections 1 mL fractions every minute; the highest peak fractions were collected and 
run on 10% SDS gel. 
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The fractions corresponding with the large bands from the 10% SDS gel were 
combined and dialyzed.  For the dialysis, the tubing was soaked in H2O for 30 minutes. 
After this, the fractions were carefully pipetted into the dialysis tubing.  150 mL of 
enzyme storage buffer (50mM Tris pH 7.9, 400 mM KCl, 0.1 mM EDTA, and 50% 
Glycerol) + 1mM DTT (added 150µL fresh) were added to a 200 mL flask with magnetic 
stir bar.  The dialysis tubing with the fractions were placed in the tubing and allowed to 
stir at 4 °C for 5 hours.  The samples were then removed and frozen at -20 °C. 
Protein Concentration Assay 
Bovine Serum Albumin (BSA) was used as the standard concentration, BSA= 1 
µg/ µL.  Increasing amounts of the samples were loaded onto a 10% SDS gel and 
compared to BSA as described in Table 2.8. 
 
 
DNA 1 µL 2 µL 3 µL 5 µL 7 µL 10 µL 
Loading 
Dye (1Xor 
2X) 
(1X) 
20 µL 
(1X) 
20 µL 
(1X) 
20 µL 
(2X) 
15 µL 
(2X) 
13 µL 
(2x) 
10 µL 
 
Table 2.8: DNA dilutions for concentration analysis 
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Activity Assay 
Twenty two mL of 28% Acrylamide-urea gel, 100 µL of 10% APS and 20 µL of 
TEMED were poured for the samples of N4A and N4S along with a new sample N4F. 
The gel was pre-run for 30 minutes at 200 volts; 1X TBE buffer was used.  The wells 
were washed of urea before the samples were loaded by pipetting out each well.  The 
samples (N4A, N4S, and N4F) were diluted using enzyme storage buffer (50 mM Tris pH 
7.9, 400 mM KCl, 0.1 mM EDTA, 50% Glycerol and 1 mM fresh DTT) according to 
their concentrations as determined by the concentration assay.  A mix (see Table 2.9) 
with radioactive RNA was made, on ice, with the addition of the radioactive isotope, 
Phosphorous (32P).  The mix was added to the samples of varying concentrations.  There 
were 9 total samples and 1 extra, giving 10 total samples.  The radioactive mix was 
prepared behind a shield. 
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50 mM Tris 81 µL 
100 mM KCl 8.1 µL 
1 mM DTT 1.62 µL 
5 mM Mn2+ 8.1 µL 
RNAsin 4.5 µL 
TRS (32P labeled RNA) 18 µL 
H2O 40.7 µL 
 
Table 2.9: Volumes of radioactive mix and mutant protein  
  
 
9 µL of the radioactive mix was added to 1 µL of each of the 9 samples (DNA + enzyme 
storage buffer).  However, additional radioactive mix was not added to the samples 
already containing radioactive mix (see Table 2.10).  The samples, after the radioactive 
mix addition, were incubated at 37°C for 1 hour.  10 µL of loading dye was added to each 
sample and heated for 3 minutes on a hot plate.  The wells were washed, and the samples 
were loaded onto the 28% Acrylamide-Urea gel.  The gel exposed to phosphoimage film 
overnight. Radioactive imaging was used to read the phosphoimage. 
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Sample DNA Enzyme Storage Buffer (or 
Radioactive mix if noted) 
Wild Type (1250 ng/ µL)   
142 ng 1.1 µL a 8.9 µL b 
71 ng 5 µL (a+b)  5 µL c 
35.5 ng 5 µL (a+b+c) 5 µL d 
17.75 ng 5 µL (a+b+c+d) 5 µL 
N4A 83 ng/ µL   
142 ng 1.7 µL  8.3 µL   (radioactive mix) 
71 ng 8.6 µL a 1.4 µL b 
35.5 ng 5 µL (a+b) 5 µL c 
17.75 ng 5 µL (a+b+c)  5 µL 
N4S 71 ng/ µL   
142 ng 2 µL  8 µL  (radioactive mix) 
71 ng 1 µL 9 µL  (radioactive mix) 
35.5 ng 5 µLa 5 µL b 
17.75 ng 5 µL (a+b) 5 µL 
N4F 400 ng/ µL   
Table II-J continued 
142 ng 3.6 µL a 6.4 µL b 
71 ng 5 µL (a+b) 5 µL c 
35.5 ng 5 µL (a+b+c) 5 µL d 
17.75 ng 5 µL (a+b+c+d) 5 µL 
 
Table 2.10: Dilution series used for phosphoimage 
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Hexamer Formation of N4F Tested 
FPLC was used in order to test the hexamer formation of the N4F mutant protein. 
The Superdex 200 column was implemented.  The protein sample was injected into the 
loop with a 1mL syringe.  Fractions were collected, and were analyzed by the FPLC 
program for hexamer and monomer formation. 
Protein Expression Assay for N4F 
Protein Expression for N4F, Fast Protein Liquid Chromatography (FPLC) 
purification, protein concentration assay, and the activity assay were carried out as they 
had been for N4A and N4S (see above).  For the protein expression of N4F, instead of 
running two elutions as was done for N4A and N4S, 3 elutions were run.  N4F was also 
run along side N4A, N4S, and wild type in a 10% SDS gel for concentration analysis. 
The volumes loaded into the 10% SDS gel are given in Table 2.11. 
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N4A (DNA) 
12.1 µL 
(2X loading 
dye) 
8 µL 
N4S (DNA) 
14.0 µL 
(2X loading dye) 
6 µL 
N4F (DNA) 
20 µL 
(1X loading dye) 
1 µL 
WT (DNA) 
20 µL 
(1X loading dye) 
1 µL 
BSA DNA) 
20 µL 
(1X loading dye) 
1 µL 
 
Table 2.11: Volumes added to 10% SDS gel for concentration analysis 
 
 
Re-sequencing of N4S and N4S 1.43 
Two concentrations of N4S (1.87ng/µL and 1.43ng/µL) were obtained and re-
sequenced. 0.25 µg/µL of each sample were needed.  To facilitate this, 1.8 µL of N4S 
1.43 was added to 7.2 H2O. 1.4 µL of N4S 1.87 was added to 8.6 µL of H2O.  2 µL of 
each DNA in H2O was then added to 2 µL of T7 terminator, and 2 µL of Big Dye for a 
total of 6 µL.  Sequencing PCR was run on the samples: 2 minutes at 94°C (1X) 94°C for 
15 seconds, 55°C for15 seconds, 72°C for 1 minute, and 72°C for 2 minutes (30X).  After 
the PCR, 14 µL of H2O was added, along with 5 µL of 125 mM EDTA and 60 µL of 
ETOH.  This mixture was allowed to sit at room temperature for 15 minutes.  After this, 
the sample was spun at top speed at 4°C in the microcentrifuge.  The supernatant was 
discarded.  50 µL of 70% ETOH was added to wash the pellet, and was slowly extracted 
from the tube.  The tube was spun for 4 seconds at 4°C in the microcentrifuge; any 
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remaining 70% ETOH was removed.  The pellet was allowed to air dry, and was 
subsequently sent for analysis at Applied Biosystems for sequencing analysis.  
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CHAPTER III 
 RESULTS AND DISCUSSION  
 
 
Nsp 15 Endoribonuclease 
Mutant proteins allow researchers to isolate specific regions of the protein as well 
as study the implications the said mutation has on enzymatic activity.  The amino acid 
sequence of the protein is known as the primary sequence.  Changes to the primary 
sequence usually yield changes in the overall 3D confirmation of the protein, known as 
the tertiary structure.  Since protein form (3D confirmation) and function are interrelated, 
a change in one leads to change in the other).  In this way, mutations in the amino acid 
sequence would yield conformational changes.  
Functions of the wild type (normal) Nsp 15 endoribonuclease include binding 
RNA, recognition of uracil (U), binding of Mn2+ cofactor, and catalyzing hydrolysis of 
the RNA substrate.  These functions are thought to be fostered by the 3D conformation of 
the wild type Nsp 15.  Endoribonucleases cleave in the middle of Ribonucleic Acid 
(RNA) strands; Nsp 15 specifically cleaves at uracil (U).  Nsp 15 contains 4 conserved 
asparagine residues; it was hypothesized that one of these residues may be important for 
substrate recognition.  For Nsp 15, the substrate is RNA (3).   
With mutations of the wild type Nsp 15, comparisons could be made to better understand 
the function of the wild type (WT) and analyze the structure-function relationship.  
As discovered in previous studies, wild type Nsp 15 exists in a state of dynamic 
equilibrium between two different 3D conformations: hexamers (see Figure 3.1) and 
monomers (11). It has also been suggested that the hexamer confirmation yields 
endoribonuclease activity. To test if amino acid substitution would translate into impaired 
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hexamer formation, site directed mutagenesis was used to create mutants of Nsp 15 
endoribonuclease and their endoribonuclease activities were subsequently tested.  The 
focus of this research was the activity of the wild type Nsp 15 versus that of the mutants 
N4A, N4S, and N4F. 
 
 
 
Figure 3.1:  Hexamer confirmation of Nsp 15 endoribonuclease wild type. 
The different clefts are possible RNA binding sites. More information can 
be ascertained about the catalytic sites as more is discovered about the 
amino acid structure of the protein. 
 
 
Analysis of Site Directed Mutagenesis 
Site directed mutagenesis is an excellent way to study a protein’s structural 
relationship to function. The QuikChange® kit implemented point mutations; the resulting 
protein had an amino acid change in one position only, thus the term point. Pfu mix was 
used due to its ability as polymerase to synthesize new pieces of DNA from a DNA 
template (24). For mutagenesis to take place Pfu replicates the plasmid, while leaving the 
mutated oligonucleotide primers in place; thus mutant DNA is created.  
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Oligonucleotides, also called primers, are short, single stranded pieces of DNA 
that can be used to insert into bacterial plasmids as seen in the QuikChange™ figure (see 
Figure 3.2); pET-15b was the vector used for Nsp 15.  (Bacterial plasmids are double 
stranded (ds) circular DNA; pET-15b contained the promoter sequence for T7 RNA 
Polymerase.)  The oligonucleotides have their nucleotide bases changed in such a way to 
ultimately yield a different DNA than the wild type DNA.  Ultimately this will result in a 
mutated protein when it is synthesized from the mutant DNA.  The oligonucleotides 
correspond to opposite strands of the plasmid, and allow inclusion into the plasmid by the 
polymerase Pfu. 
The parent DNA (the template) was digested by an endonuclease, Dpn I.  Dpn I is 
specific for 5´-Gm6ATC-3´; the m refers to methylation.  Bacterial DNA contains 
methylation on the Guanine (G); therefore the bacterial plasmids were digested, leaving 
the mutated DNA.  
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Figure 3.2: QuikChangeTM Site-Directed Mutagenesis  
 
 
DNA Concentration Results 
The plasmid containing the desired mutations were transformed into XL-10 gold 
cells and grown in culture in Luria-Bertani (LB) medium with ampicillin for selection. 
Expression of Nsp15 in log-phase cells (Optimum density between 0.8 and 1.0) were 
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induced by the addition of IPTG allowing transcription of Nsp15 DNA. The DNA gel 
with purified N4A and N4S DNA can be seen in Figure 3.3. 
 
 
 
1                      6                      11 
Figure 3.3: DNA gel electrophoresis: 1St lane = molecular 
weight marker; 2nd -5th lanes = collections 1-4 N4A; 6th 
lane = purified N4A DNA; 6th-10th lanes = collections 1-4 
N4S; 11th    lane = purified N4S 
 
 
Sequencing PCR was run on the purified DNA to ensure the correct mutation had 
taken place.  The purified DNA concentration for N4A and N4S were determined using 
UV spectroscopy.  N4A was found to be 0.19µg/µL; N4S was found to be 0.26 µg/ µL.  
The purified DNA pellets were sent for analysis, as seen in the Electropherograms in 
Figure 3.4 for N4A.  
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Figure 3.4: Nucleotide analysis of N4A promoter sequence. The nucleotide 
sequence was used to determine that the correct mutation had taken place, and no 
spontaneous mutations had occurred. The individual nucleotide bases can be seen 
below the curves.  
 
 
 
As seen in Figure 3.4, each nucleotide in the DNA N4A terminator and promoter 
sequences was analyzed.  The nucleotides corresponding with the correct mutations were 
then confirmed.  
 
 
 
53 
Analysis of Protein Expression assay for N4A and N4S 
 S cells containing T7 RNA polymerase were used in the transformation of the 
mutant DNA.  T7 RNA polymerase was necessary in order to make the mutant protein. 
The S cells were the competent cells of choice due to their mutations in protease genes 
thereby decreasing degradation of expressed proteins. The protein was extracted and 
fractions from the Talon Nickel Affinity column were saved throughout the assay.  The 
protein extraction gel for N4A and N4S can be seen in Figure 3.5.  
Each lane shows protein that was eluted from the column.  The final elutions, E1 
and E2 contain the purified N4A and N4S.  The total (2nd lane) contains large amounts of 
extraneous protein along with N4A and N4S.  The load (3rd lane) shows the protein 
(including extraneous protein) that was added directly to the Talon-Nickel Affinity 
column.  The flow through (4th lane) shows the extraneous protein that passed through the 
column via gravity filtration.  The low concentration imidazole wash (5th lane—wash2) 
contains more extraneous protein that may have transiently bound to the column, along 
with other extraneous protein that was not removed in the flow through.  N4A and N4S 
were bound to the Talon resin via histidine tags.  In order to remove the desired protein 
from the column, higher concentration of imadazole was used.  Imidazole contains 
histidine and removes N4A and N4S by eluting it from the column bound to the histidine. 
N4A and N4S are somewhat purified here, but not completely; a few extra bands are seen 
for extraneous proteins. 
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 1     2       3      4       5        6      7                    8     9     10    11      12     13 
Figure 3.5: N4A and N4F protein extraction gel. N4A:1st lane = protein bench 
marker; 2nd lane = total protein; 3rd lane = supernatant loaded onto Talon column; 
4th lane = flow through; 5th = low imadazole wash; 6th – 7th lanes = elutions of 
purified N4A. N4S:  8th lane = total protein; 9th = supernatant loaded onto column; 
10th lane = flow through; 11th lane = low imadazole wash; 12th – 13th lanes = 
elutions of purified N4S. 
 
 
FPLC Analysis 
In order to further purify the protein, Fast Protein Liquid Chromatography was 
run.  The MonoQ column used in FPLC separated the protein according to charge.  Salt 
buffers were used during the filtration to affect the charge of the column, thus separating 
the protein at different fractions.  The flow diagrams from the FPLC show the fractions in 
which the protein is contained (see Figure 3.6 for N4S; see Figure 3.7 for N4A).  The 
pink and red lines on the diagram shows the points of injection for the high and low salt 
buffer solutions. The large, erratic recording shows an air bubble in the sample.  The 
protein was found to be in fractions 24-30, as seen by the smooth curves at the right of 
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the diagram.  (The last smooth curve was affected by the salt buffers, and does not 
contain protein). 
 
 
 
Fractions:      24                30 
Figure 3.6: FPLC diagram for N4S. Protein can be seen in the smooth curves 
corresponding to fractions 24-30. 
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              24         30 
Figure 3.7: FPLC diagram for N4A; fractions 24-30 contained protein as 
modeled by the smooth curves labeled above. 
 
 
The fractions with protein were run on a 10% SDS page gel, as seen in Figure 3.8.  
The fractions with the largest bands were combined, and used for further analyses as the 
sample for N4A and N4S. 
Concentration Analysis 
N4A and N4S were compared against the standard Bovine Serum Albumin 
(BSA); a 10% SDS page gel was run in order to analyze the intensities of each band (see 
Figure 3.9.  As compared to BSA= 1 µg/ µL, N4A was found to be 0.083 µg/µL and N4S 
was found to be 0.071 µg/µL. N4F, another mutant protein sample, was found to be 0.4 
µg/µL  
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                    N4A      N4S                                               
 
Figure 3.8: Fractions 24-30 collected from MonoQ FPLC analysis. The darkest 
bands were combined (separately for N4A and N4S) and dialyzed for storage. 
 
 
 
       1     2     3     4     5      6       7      8         9    10   11    12   13   14   15 
 
Figure 3.9: Concentration gel for N4A and N4S. N4A: 1st lane = protein 
bench marker; 2nd lane = BSA; 3rd lane = 1 µL; 4th lane = 2 µL; 5th lane = 
3 µL; 6th lane = 5 µL; 7th lane = 7 µL; 8th lane = 10 µL; N4S: 9th lane = 
BSA; 10th lane = 1 µL; 11th= 2 µL; 12th lane = 3 µL; 13th lane = 5 µL; 14th 
lane = 7 µL; 15th lane = 10 µL. 
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A concentration gel was also run in order to compare all mutants (N4A, N4S and N4F) 
with the wild type (see Figure 3.10). 
 
 
 
1            2      3                                         4   5 
Figure 3.10: All mutants compared with wild type and 
BSA: (from left) Protein bench marker, BSA, N4A, N4S, 
N4F, and wild type. 
 
 
 A dilution series of N4F at 2µL, 4 µL, and 6 µL was carried out on a 10% SDS 
page gel as seen in Figure 3.11. 
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                                                                            1      2        3              4                              
Figure 3.11: N4F in series with increasing concentration (from 
left) 6 µL, 4 µL, 2 µL, protein bench marker.  
 
 
Activity Analysis 
N4A, N4S, N4F, and wild type were run on a 28% Acrylamide-Urea gel, and 
radioactive RNA (marked with a radioactive isotope, 32P) was added.  The gel was 
blotted onto a film, and imaged; the image was visible due to the radioactive isotope of 
phosphorous, 32P, which was used to label the RNA substrate (see Figure 3.12).  If 
cleavage was attained, it could be inferred that the mutation did not affect the activity of 
the protein.  If cleavage was not attained, it could also be inferred that the activity was 
affected, and further tests should be run.  
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       N4A           N4F           N4S            WT 
Figure 3.12: Phosphoimage yielding activity results: (from left) N4A, 
N4S, N4F, wild type 
 
 
 
     N4A      N4F    N4S      WT 
Figure 3.13: Phosphoimage obtained with old TRS probe: (from left) 
N4A, N4F, N4S, and Wild Type 
 
 
 
 
 
Product 
Substrate
Substrate
Product 
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The second bands in the above figure are the RNA cleavage products of Nsp 15 
mutants and wild type.  Results from the phosphoimage showed that N4A and N4S 
retained activity, whereas N4F did not.  The TRS radioactive probe (radiolabeled RNA) 
should be fresh to attain best results.  An old probe was used for one trial, and the image 
was unclear.  The assay was run for a second time with a new TRS probe, and the image 
was clear, (see Figure 3.13 for fuzzy image obtained with old probe). 
To better compare the wild type to N4F, a 28% acrylamide-urea gel was run.  
N4F and wild type were imaged together for better comparison (see Figure 3.14).  
 
 
 
 
WT                                                N4F 
Figure 3.14: Phosphoimage of wild type and N4F. N4F has no cleavage 
product (2nd band), and therefore no activity  
 
Substrate 
Product 
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Since N4F had no activity in either phosphoimage, N4F DNA was transformed 
into S cells and the protein expression assay was repeated.  It was found that N4F was not 
expressed; the protein seen in the gel (see Figure 3.15) was extraneous.  The FPLC result 
showed no protein in any of the fractions (see Figure 3.16).  After conducting a re-
sequencing PCR, N4F was found to be mutated at positions other than the 4th amino acid 
position. 2 other samples labeled N4S were thought to possibly be the true N4F.  (It must 
be noted that the N4S that was created by site directed mutagenesis was truly N4S. N4S 
1.87 and N4S 1.43 were two additional samples that were also labeled N4S).  One of the 
samples had a concentration of 1.87µg/µL; the other had a concentration of 1.43µg/µL. 
Since the original sample thought to be N4F had a concentration of 1.87, it was thought 
that the true N4F also had this concentration.  Both N4S 1.87 and N4S 1.43 were diluted 
to 0.25 µg/µL and a sequencing PCR was conducted.  It was found that N4S 1.43 was 
truly N4F5G, and N4S 1.87 was also incorrect (figures not shown).  None of the samples 
only had the N4F mutation. 
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                  1         2         3      4 
Figure 3.15: N4F: no protein in low imadazole wash or elutions. (Lanes 
with protein from the left) 1st lane = protein bench marker; 2nd lane = total 
protein; 3rd lane = supernatant loaded onto the column; 4th lane = flow 
through. 
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Figure 3.16: N4F FPLC; No protein was observed in the fractions 
from the FPLC 
 
 
In order to make sure the N4F protein was not left in the pellet, thereby making it 
insoluble, the pellet was run on an extraction gel, along with the total, wash, and elutions. 
No protein was found to be in the pellet; this result confirmed the suspicion that N4F was 
not expressed (see Figure 3.17). 
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 1                                         2    gap   3       4 
Figure 3.17: No protein was found in the sample from the pellet 
(see gap between 2nd and 3rd lane) 
 
 
Hexamer Formation Investigated 
Gel filtration was implemented in the FPLC column Superdex 200 in order to test 
the hexamer and monomer formation of N4F in comparison with wild type.  Gel filtration 
separated the proteins according to size.  No hexamers were found in N4F and the 
monomer peak migrated differently than wild type monomers.  This result would indicate 
that a subunit larger than a monomer, but smaller than a hexamer was obtained; this is 
impossible.  Additional experimentation will be necessary to explore the structure of N4F 
(see Figure 3.18). 
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Figure 3.18: Conformations as found in fractions from FPLC. Top arrow 
points to the wild type hexamer peak; the shifted N4F peak is shown by 
the middle arrow. The bottom arrow shows the wild type and monomer 
peak. Equilibrium between monomers and hexamers is usual for wild type 
protein. 
 
 
 
 
 
 
 
 
 
67 
 
Discovery of N4F5G 
N4F5G (formerly labeled N4S 1.43) was run on a 10% SDS page gel after protein 
extraction via a Talon-Nickel affinity column (see Figure 3.19). 
 
 
 
 
 
          L     FT   E1     E2      E3    E4      
Figure 3.19: N4F5G with protein in elutions: (from left) Load, 
flow through, elution 1, elution 2, elution 3, elution 4 
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Protein was found in the elutions from the Talon-Nickel affinity column 
indicating that the protein had in fact come off of the column, and was a soluble protein. 
N4F5G was tested with FPLC, and protein was found in the fractions (see Figure 3.20), 
as predicted by the gel in Figure 3.19. 
 
 
 
Figure 3.20: N4F5G protein seen in fractions from FPLC 
 
 
Lys S Cells vs. S Cells 
Lys S cells express lysosyme thereby helping to prevent expression of Nsp 15 
prior to adding IPTG.  S cells are deficient in RNase E. N4F5G was transformed into Lys 
S cells and S cells.  Both cell lines were grown and the protein was extracted.  In the 10% 
SDS page gel, the protein made from the Lys S cells was not in the elutions from the 
column resin (E1, E2, and E3), whereas the proteins grown in the S cells did appear in the 
elutions (see Figure 3.21). 
69 
 
 
 
S cells:         1      2       3     4     5                                           Lys S cells:    6   7      8 
Figure 3.21: N4F5G grown in S cells versus N4F5G grown in Lys S cells. There was no 
protein in the elutions from the Lys S cells. If there had been protein there would be 
bands before band 6 (from left). 
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CHAPTER V 
 SUGGESTIONS FOR FUTURE RESEARCH 
 
 
For a more complete understanding of Nsp 15 endoribonuclease, more mutant 
proteins should be created, and the results quantified.  By doing this, more information 
about the structure of the 4th amino acid position, along with other amino acid positions 
would be elucidated.  With this information, more information can be gathered 
concerning the possible binding sites for the RNA substrate, and the amino acid 
sequences most responsible for the active 3D confirmation. 
Further research should include testing the activity of N4F5G.  In previous 
studies, E3A mutations in a similar ribonuclease caused conformational changes in the 
protein thereby affecting enzyme activity.  With this in mind, mutating amino acids near 
the 3rd amino acid may result in changes in 3D conformation.  If decreased or no activity 
is found, further experiments should be conducted to determine whether the activity 
change is due to an inability to bind the Mn 2+ cofactor, impaired RNA recognition, or to 
an inability to form hexamers. 
In order to determine whether the mutant Nsp 15 bind Mn2+, a titration 
experiment should be performed.  Graphs of percent substrate cleaved vs. Mn2+ 
concentration could then be constructed.  The graphs would yield information on the 
binding affinity of the mutant for Mn2+.  From previous literature, it is hypothesized that 
the Mn2+ cofactor induces a conformational change in Nsp 15, possibly to its catalytically 
active form.  It is also recommended to test conformational changes produced by the 
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addition of Mn2+ via intrinsic fluorescence (25). All mutant proteins would be compared 
to wild-type protein to look for abnormalities.  
Mutant proteins could also be inactive because they fail to bind to the RNA 
substate.  To test this possibility, fluorescence quenching could be used as the method to 
detect the bound RNA. The RNA substrate will be labeled with a fluorescent compound, 
and if Nsp15 binds to it, then the fluorescent signal will be decreased (25).  
Lastly, conformational effects should be tested via native gel electrophoresis and 
gel filtration.  Previous research has shown that Nsp15 forms a hexamer in solution 
(Guarino).  Native Nsp 15 has a molecular weight of around 240,000 kDa, although the 
predicted molecular mass is only 40,000 kDa.  This would help in adding to the literature 
on the active confirmation of Nsp 15.  Once the active confirmation is better understood, 
more information can be gathered on how the protein functions in vivo with other 
proteins, thereby taking one step closer to understanding the viral mechanism for 
structure based drug design. 
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CHAPTER IV 
 CONCLUSION 
 
By inserting various amino acid mutations into the Nsp 15 endoribonuclease, it 
was found that endoribonuclease activity was affected.  N4F caused the endoribonuclease 
activity to cease.  The N4A mutation as well as the N4S mutation retained activity.  From 
this, it can be inferred that the N4F mutation caused severe hexamer disruption thereby 
ceasing endoribonuclease activity.  It must also be noted that the N4F used in the activity 
assay was severely mutated in positions exceeding the 4th amino acid position.  More 
research should be done with the F mutation only in the 4th amino acid position, (more 
detail on implications for future research can be found in Chapter V).  
Knowledge of Nsp 15 endoribonuclease may one day lead to the discovery of 
structure based drugs used to treat SARS.  The protocols followed in these experiments 
may be specific for Nsp 15, but the discovery process and pattern of thought necessary 
can be applied to all areas of scientific research.  It was the goal of this research endeavor 
to add to the literature on Nsp 15 endoribonuclease by creating a better understanding of 
the structural and functional capabilities of Nsp 15, and how they can be manipulated for 
treatment. 
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Anderson Cancer Center. 
 
• “Detection of Salmonellae in bovine feces by real time PCR.” Sara D. 
Lawhon, G. Alex Klarenbeek, Roberta Pugh, Doris Hunter, William Miller, 
Carlos Rossetti, Maravet Baig, Andreas Bäumler, L. Garry Adams.  (for 
publication) 
 
• Conducted research in Dr. L. Garry Adams’ lab 2004-2005 
 
• Conducted research in Dr. Linda A. Guarino’s lab 2005-2006 for 
Honors Undergraduate Research Fellows 
MEMBERSHIPS & HONOR SOCIETIES 
 • Texas A&M University Honor Council 
• Phi Eta Sigma 
• Sigma Xi 
• Golden Key International Honour Society 
• National Society of Collegiate Scholars 
• Texas A&M Pre-Medical Society 
• Aggie Women in Leadership 
